Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions

Miculas, Denisa Claudia; Negru, Paul Andrei; Bungău, Simona; Behl, Tapan; Hassan, Syed Shams ul; Ţiţ, Delia Mirela

doi:10.3390/cells12010131

Cited by 33 publications

(24 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alzheimer’s disease (AD) is a neurodegenerative condition defined by the gradual death of brain cells through many signaling pathways, including glutamate, PI3K/Akt, extracellular signal-regulated kinase (ERK), HMGB, and Necrotic factor kappa B (NFkB) ( Kao et al, 2009 ; Srinivasan and Lahiri, 2015 ; Miculas et al, 2022 ). Studies showed that GA blocked the activity of NF-kB as a key element of neurodegenerative disease pathogenesis ( Wang et al, 2011 ).…”

Section: Licorice In Alzheimer’s Diseasementioning

confidence: 99%

“…Recent research has found that HMGB1 plays a pathogenic role in memory impairment, primarily via the TLR4 and RAGE signaling pathways ( Rong et al, 2021 ; Miculas et al, 2022 ). Furthermore, HMGB1 neutralization has been shown to reduce cognitive dysfunction and post-TBI cognitive impairment ( Hei et al, 2018 ; Okuma et al, 2019 ).…”

Section: Licorice In Alzheimer’s Diseasementioning

confidence: 99%

See 1 more Smart Citation

A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases

et al. 2023

View full text Add to dashboard Cite

The use of medicinal plants has grown in popularity in recent decades because, as natural ingredients, they have fewer adverse effects and are more effective than synthetic alternatives. As a small perennial herb, Glycyrrhiza glabra L. (Licorice) has been investigated for its therapeutic efficacy against neural disorders mainly ischemic stroke as well as the neurodegenerative diseases such as dementia and Alzheimer’s disease, and Parkinson’s disease which has been attributed to its HMGB inhibitory function, reactive oxygen scavenging and anti-inflammatory activity. The objective of current review is to review the evidence for the pharmacological effects of licorice and its vital active components on neurological disorders and the underlying signaling networks. We reviewed Papers published from 2000.1.1 up to 2 January 2023 in web of science, Google Scholar and PubMed data bases using key words including “Licorice,” “Glycyrrhiza glabra L.,” “Glycyrrhizic acid,” “brain,” “neurodegenerative disease,” “Alzheimer’s,” and “Parkinson” were used to search in title/abstracts. Licorice extract and/or its active components can be used safely in therapeutic doses for optimizing the management of a multiple neurodegenerative disorders, and hampering the extent of neural tissue injury and neurologic deficits subsequent to cerebrovascular accidents.

show abstract

Section: Licorice In Alzheimer’s Diseasementioning

confidence: 99%

Section: Licorice In Alzheimer’s Diseasementioning

confidence: 99%

A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The current drug agents licensed for Alzheimer's disease are restricted in scope because they provide secondary care and are focussed on treating behavioural symptoms and delaying progression. All currently known treatments work by altering the levels of particular neurotransmitters in the brain, principally acetylcholine (ACh) and glutamate (Miculas et al, 2022). Only a few pharmaceutical agents have been authorised by the Food and Drug Administration (FDA), and some have even been stopped because of negative effects (Sharma, 2019).…”

Section: Progression and Early Diagnostic Role Of Biomarkers In Admentioning

confidence: 99%

Alzheimer's disease: A role of biomarkers in early diagnosis and evidences from African ethnomedicinal knowledge

Balkrishna

Verma

Singh

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurological ailment that primarily affects the elderly and necessitates an efficient treatment regimen backed up by extensive care. Despite advancement in the in vivo imaging techniques focussing on early diagnosis of reliable biomarkers using novel magnetic resonance imaging (MRI) and positron emission topography (PET) scans, AD remains largely unexplained and effective preventative and treatment strategies are still lacking. Consequently, research groups are constantly attempting to improve its early detection, using both invasive and non‐invasive techniques with established core markers like Aβ and Tau (t‐tau and p‐tau) proteins. Unfortunately, African American and other black races are facing an increasing burden of closely associated risk factors, and only a few attempts have been made to find effective complementary and alternative therapies for AD cure and management. A greater epidemiology and natural product research are required to deal with the concurrent rise of dementia among quickly ageing African population, which so far have largely been ignored in addition to a disparity in the AD risk factors. We have tried to bring attention to the issue by reviewing up on this predisposition while generating a perspective on how race may affect AD risk and expression. This article also puts emphasis on finding new research leads from African phytodiversity while presenting several of the important species along with their biological agents found helpful in dementia related symptoms.

show abstract

“…Despite its prevalence and devastating impact, presently, there is no effective treatment that can stop or even slow down the disease progression 13–15 . Only two classes of drugs are approved till now including inhibitors and antagonists 12,16 and they are effective in treating AD only symptomatically with no disease modifying effect. However, it is also reported that as of the index date of January 25, 2022, there are 143 drugs in the AD drug development pipeline 17 …”

Section: Introductionmentioning

confidence: 99%

Reactive oxygen species may cause amyloid beta aggregation by free radical polymerization

Majid,

Garg

2024

J of Applied Polymer Sci

View full text Add to dashboard Cite

Alzheimer's disease (AD), the most common form of dementia, is closely related to the overproduction of reactive oxygen species (ROS). A kinetic model based on free radical polymerization of amyloid beta (Aβ) utilizing ROS as an initiator is proposed. Kinetic parameters involved in the model are tuned with the reported experimental data on fibril molecular weight. The tuned model is used to simulate time evolution of fibril length and polydispersity of Aβ aggregates. The simulated values are compared with the reported experimental values for these fibril properties. A good agreement is observed between the model simulated fibril properties and the reported experimental data. This supports the hypothesis of ROS as the cause of Aβ aggregation using the free radical polymerization. The proposed model is also able to predict the sigmoidal growth of fibrils at different set of parameter values. Sensitivity analysis has been performed to check the reliability of the proposed model. It is envisaged that the proposed model will be helpful to elucidate ROS‐based therapeutic strategies for AD treatment in near future.

show abstract

Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions

Cited by 33 publications

References 115 publications

A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases

A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases

Alzheimer's disease: A role of biomarkers in early diagnosis and evidences from African ethnomedicinal knowledge

Reactive oxygen species may cause amyloid beta aggregation by free radical polymerization

Contact Info

Product

Resources

About